Novartis committed to provide equivalent of more than USD 3 million in relief aid to Japan earthquake victims

  • Support includes direct financial assistance to relief organizations and donation of essential medicines, including pain relieving drugs

  • Employees encouraged to make personal contributions to nationally recognized relief organizations to be matched with company funds

Basel, March 17, 2011 - Novartis has committed to providing the equivalent of over USD 3 million in immediate relief aid to the victims of the recent earthquake in Japan. The support includes both direct financial aid to relief agencies as well as donations of essential medicines, including pain relieving drugs.

"It is still difficult to fully comprehend the human impact of the recent natural disaster in Japan as well as the continued uncertainty hanging over the citizens and residents of that country," said Daniel Vasella, Chairman of Novartis. "We are committed to provide humanitarian relief to those affected. We are also working closely with our team in Japan to maintain the continuity of our business operations, to ensure that physicians and patients continue receiving the medicines they need."

Novartis employees worldwide are encouraged to make cash contributions to nationally recognized relief organizations in support of the victims of the earthquake. These donations will then be matched by the company.

The company will also work with relief organizations as well as the Japanese authorities to identify where assistance can be provided on a longer-term basis to ensure that there is sustainable support for people impacted by this tragic natural disaster.

# # #

Novartis Media Relations

Eric Althoff
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
eric.althoff [a] novartis (p) com

e-mail: media.relations [a] novartis (p) com

Beth Calitri
Novartis Global Media Relations
+41 61 324 7973 (direct)
+41-79 523 0198 (mobile)
beth.calitri [a] novartis (p) com

Download:

Media release

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.


This site uses cookies and analysis tools to improve the usability of the site. More information. |